Source-grounded facts extracted from Prestige Consumer Healthcare Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jeffrey Zerillo departed as Senior Vice President, Operations at Prestige Consumer Healthcare Inc..
“On August 10, 2026, Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. (the “Company”) of his decision to retire from his position as Senior Vice President, Operations and from all other positions he holds with the Company, effective August 14, 2026.”
Prestige Consumer Healthcare Inc. completed an acquisition involving Foundation Consumer Brands, LLC and certain of its affiliates for $1.045 billion in cash (closed 2026-06-12).
“On June 12, 2026, the Borrower and Medtech Products Inc. (“MedTech”), a wholly-owned subsidiary of the Company, completed the previously announced acquisition of Breathe Right® and certain other brands (the “Breathe Right Business”) from Foundation Consumer Brands, LLC and certain of its affiliates, pursuant to an Asset Purchase Agreement, dated as of March 19, 2026 (the “Purchase Agreement”), for a purchase price of $1.045 billion in cash (the “Transaction”).”
Prestige Consumer Healthcare Inc. amended revolving credit of $225 million with Citibank, N.A., as the administrative agent maturing the date that is five years from the Closing Date.
“the ABL Amendment (i) increased the aggregate commitments under the ABL Credit Facility to $225 million and (ii) extended the maturity date of the ABL Credit Agreement to the date that is five years from the Closing Date”
Prestige Consumer Healthcare Inc. incurred credit facility of $1.045 billion with Citibank, N.A. as administrative agent at Term SOFR plus 2.00%.
“Proceeds of term loans borrowed under the Term Loan Credit Agreement in the amount of $1.045 billion were used to finance the Transactions (as defined below) that occurred on the Closing Date”
Prestige Consumer Healthcare Inc. amended Amendment No. 10 with Citibank, N.A. valued at $225 million (effective 2026-06-12).
“the Company and the Borrower entered into Amendment No. 10 (the "ABL Amendment") to the credit agreement governing the Company's asset-based revolving line of credit (as amended, the "ABL Credit Agreement") originally entered into on January 31, 2012, by and among the Company, the Borrower, certain subsidiaries party thereto as guarantors, the lenders party thereto and Citibank, N.A., as the administrative agent.”
Prestige Consumer Healthcare Inc. entered into Term Loan Credit Agreement with Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets valued at $1.045 billion (effective 2026-06-12).
“On June 12, 2026 (the "Closing Date"), Prestige Consumer Healthcare Inc. (the "Company") and its wholly-owned subsidiary, Prestige Brands, Inc. (the "Borrower"), entered into that certain Term Loan Credit Agreement (the "Term Loan Credit Agreement") by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets, as joint lead arrangers and joint bookrunners.”
Prestige Consumer Healthcare Inc. entered into Sale and Purchase Deed with Tailor Investments Pty Limited and Standive Pty Limited valued at approximately $150 million in cash (effective 2026-05-10).
“On May 10, 2026, PBH Australia Holding Company Pty Limited ("Purchaser"), an Australian company and a wholly owned indirect subsidiary of Prestige Consumer Healthcare Inc. (the "Company"), and Care Pharmaceuticals Pty Limited ("Care"), an Australian company and a wholly owned indirect subsidiary of the Company, entered into a definitive agreement (the "Sale and Purchase Deed") with Tailor Investments Pty Limited and Standive Pty Limited, both Australian companies (the "Sellers"), Steven David Sher, Delon Badler and Clive Howard Sher.”
Prestige Consumer Healthcare Inc. reported financial results for the fiscal quarter and year ended March 31, 2026.
“On May 13, 2026, the Company announced financial results for the fiscal quarter and year ended March 31, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2026 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.”
Prestige Consumer Healthcare Inc. entered into Asset Purchase Agreement with Foundation Consumer Brands, LLC valued at $1.045 billion in cash (effective 2026-03-19).
“On March 19, 2026, Prestige Brands, Inc. (“Purchaser”), a Delaware corporation and a wholly-owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), entered into a definitive agreement (the “Asset Purchase Agreement”) with Foundation Consumer Brands, LLC (“Foundation”), a Delaware limited liability company. The Asset Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire certain assets and assume certain liabilities primarily related to a portfolio of over-the-counter consumer health products, including Breathe Right® and certain other brands, for $1.045 billion in cash”
Christine Sacco was appointed as Chief Operating Officer at Prestige Consumer Healthcare Inc..
“On January 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced that the Company’s Chief Financial Officer, Christine Sacco, age 49, has also been appointed Chief Operating Officer, effective January 6, 2025.”
Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2024 results: revenue $1,125.4 million, net income $209.3 million, EPS $4.17. Guidance initiated.
“Reported revenues for the fiscal year 2024 totaled $1,125.4 million compared to revenues of $1,127.7 million for the fiscal year 2023. Revenues increased 0.2% excluding the impact of foreign currency. Revenue performance for the fiscal year was driven by strong International OTC segment performance and strong Eye & Ear Care, GI, and Dermatological category sales in North America, partially offset by lower Women’s Health, Cough & Cold, and Analgesic category sales and the strategic exit of private label revenues. Reported net income for fiscal 2024 of $209.3 million compared to the prior year comparable period net loss of $82.3 million. Reported Fiscal 2024 diluted earnings per share was $4.17, compared to diluted loss per share of $1.65 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. reported the fiscal quarter ended March 31, 2024 results: revenue $277.0 million, net income $49.5 million, EPS $0.98. Guidance initiated.
“Reported revenues in the fourth quarter of fiscal 2024 of $277.0 million compared to $285.9 million in the fourth quarter of fiscal 2023. Revenues decreased 2.9% excluding the impact of foreign currency. The revenue decline in the quarter was attributable to the inability to supply customer orders late in the quarter in certain brands, the strategic exit of private label revenues, and a lower Women’s Health category, partially offset by growth in the International OTC segment. Reported net income for the fourth quarter of fiscal 2024 was $49.5 million versus the prior year comparable quarter’s net loss of $240.6 million. Diluted earnings per share of $0.98 for the fourth quarter of fiscal 2024 compared to a $4.83 diluted loss per share in the prior year comparable period.”
John F. Kelly was elected as Director at Prestige Consumer Healthcare Inc..
“The Company today announced that John F. Kelly, former Vice President Quality Operations and Environment, Health & Safety at Pfizer Inc. was elected to the Company’s Board of Directors on May 7, 2024.”
Prestige Consumer Healthcare Inc. reported fiscal year 2024 results: revenue $1,135 to $1,140 million, EPS approximately $4.33. Guidance raised.
“Given the strong Q3 performance, we are raising our fiscal 2024 earnings outlook. We continue to anticipate revenues of $1,135 to $1,140 million, thanks to our diverse portfolio of brands. We expect this outlook to continue to translate into industry-leading free cash flow, which positions us to continue creating long-term shareholder value through stable organic growth and strategic capital allocation,” Mr. Lombardi concluded. Prior Fiscal 2024 Outlook Current Fiscal 2024 Outlook Revenue $1,135 to $1,140 million $1,135 to $1,140 million Organic Revenue Growth 1% to 2% 1% to 2% Diluted E.P.S. $4.27 to $4.32 Approximately $4.33 Free Cash Flow $240 million or more $240 million or more”
Prestige Consumer Healthcare Inc. reported the first nine months of fiscal 2024 results: revenue $848.4 million, net income $159.9 million, EPS $3.19.
“Reported revenues for the first nine months of fiscal 2024 totaled $848.4 million, a 0.8% increase compared to revenues of $841.9 million for the first nine months of fiscal 2023. Revenues increased 1.2% versus the prior year nine-month period excluding the impact of foreign currency. The revenue growth for the first nine months was driven by solid International segment performance and strong Eye & Ear Care category sales in North America, partially offset by lower Women’s Health category sales and the strategic exit of private label revenues. Reported net income for the first nine months of fiscal 2024 totaled $159.9 million, an increase compared to the prior year comparable period net income of $158.2 million. Diluted earnings per share were $3.19 for the first nine months of fiscal 2024 increased compared to diluted earnings per share of $3.14 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. reported the third quarter of fiscal 2024 results: revenue $282.7 million, net income $53.0 million, EPS $1.06.
“Reported revenues in the third quarter of fiscal 2024 of $282.7 million compared to a $275.5 million in the third quarter of fiscal 2023. Revenues increased 2.6% versus the prior year third quarter on both a reported and organic basis. The revenue growth for the quarter was led by strong Eye & Ear Care category performance in North America and Hydralyte ® brand growth in the International segment, partially offset by an expected decline in the Cough & Cold category and the planned strategic exit of private label revenues. Reported net income for the third quarter of fiscal 2024 totaled $53.0 million, an increase versus the prior year third quarter’s net income of $52.0 million. Diluted earnings per share of $1.06 for the third quarter of fiscal 2024 increased 2.2% versus $1.04 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. amended revolving credit of $25 million increase in the aggregate revolving commitments with Citibank, N.A., as administrative agent, L/C issuer and swing line lender maturing five years from the effective date of the Amendment.
“The Amendment provides for (i) a $25 million increase in the aggregate revolving commitments of all lenders under the Credit Agreement, (ii) an extension of the maturity date of the Credit Agreement to the date that is five years from the effective date of the Amendment”
Prestige Consumer Healthcare Inc. amended Amendment No. 9 with Citibank, N.A., as administrative agent, L/C issuer and swing line lender (effective 2023-12-08).
“On December 8, 2023, Prestige Consumer Healthcare Inc. (the “ Company ”) and its wholly owned subsidiary, Prestige Brands, Inc. (the “ Borrower ”) entered into Amendment No. 9 (the “ Amendment ”) to the ABL Credit Agreement”
Prestige Consumer Healthcare Inc. reported the six months ended September 30, 2023 results: revenue $565.6 million, net income $106.8 million, EPS $2.13. Guidance reaffirmed.
“Reported revenues for the first six months of fiscal 2024 totaled $565.6 million and compared to revenues of $566.3 million for the first six months of fiscal 2023. Revenues increased 0.5% versus the prior year six-month period, excluding the impact of foreign currency. The revenue growth for the first six months was driven by International OTC segment performance and strong Dermatological category sales in North America, offset by lower Women’s Health category sales and the strategic exit of private label revenues. Reported net income for the first six months of fiscal 2024 totaled $106.8 million versus the prior year comparable period net income of $106.3 million. Diluted earnings per share were $2.13 for the first six months of fiscal 2024 increased compared to diluted earnings per share of $2.11 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. reported the fiscal quarter ended September 30, 2023 results: revenue $286.3 million, net income $53.6 million, EPS $1.07. Guidance reaffirmed.
“Reported revenues in the second quarter of fiscal 2024 of $286.3 million compared to a record $289.3 million in the second quarter of fiscal 2023. Revenues decreased 0.7% versus the prior year second quarter excluding the impact of foreign currency. The revenue performance for the quarter was led by Cough & Cold and Ear & Eye Care category performances in North America and strong International OTC segment growth versus the prior year comparable period, offset by declines in certain other categories and the planned strategic exit of private label revenues. Reported net income for the second quarter of fiscal 2024 totaled $53.6 million, compared to the prior year second quarter’s net income of $51.0 million. Diluted earnings per share of $1.07 for the second quarter of fiscal 2024 increased 5.4% versus $1.02 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. reported the fiscal quarter ended June 30, 2023 results: revenue $279.3 million, net income $53.3 million, EPS $1.06. Guidance reaffirmed.
“Reported revenues in the first quarter of fiscal 2024 of $279.3 million increased 0.8% from $277.1 million in the first quarter of fiscal 2023.”
Prestige Consumer Healthcare Inc. reported Fiscal 2024 results: revenue $1,135 to $1,140 Million, EPS $4.27 to $4.32. Guidance initiated.
“Initial Full-Year Fiscal 2024 Revenue and EPS Expectation of $1,135 to $1,140 Million and $4.27 to $4.32, respectively”
Prestige Consumer Healthcare Inc. reported the fiscal year ended March 31, 2023 results: revenue $1,127.7 million, net income net loss of $82.3 million, EPS diluted loss per share of $1.65.
“Reported revenues for the fiscal year 2023 totaled $1,127.7 million, an increase of 3.8%, compared to revenues of $1,086.8 million for the fiscal year 2022.”
Prestige Consumer Healthcare Inc. reported the fourth quarter ended March 31, 2023 results: revenue $285.9 million, net income net loss of $240.6 million, EPS diluted loss per share of $4.83.
“Reported revenues in the fourth quarter of fiscal 2023 of $285.9 million increased 7.1% from $266.9 million in the fourth quarter of fiscal 2022.”
Prestige Consumer Healthcare Inc. reported fiscal year 2023 results: revenue $1,120 and $1,122.
“With one quarter to go in fiscal year 2023 we anticipate sales between $1,120 and $1,122 equating to over 3% growth on top of our record fiscal 2022 results.”
Prestige Consumer Healthcare Inc. reported third fiscal quarter ended December 31, 2022 results: revenue $275.5 million, net income $52.0 million, EPS $1.04.
“Reported revenues in the third quarter of fiscal 2023 of $275.5 million increased 0.4% from $274.5 million in the third quarter of fiscal 2022. Revenues increased 1.8% excluding the impact of foreign currency. The revenue growth for the quarter was led by strong performance in our International OTC segment and strong Cough & Cold category sales versus the prior year comparable period. Reported net income for the third quarter of fiscal 2023 totaled $52.0 million, compared to the prior year third quarter’s net income of $50.2 million. Diluted earnings per share of $1.04 for the third quarter of fiscal 2023 compared to diluted earnings per share of $0.99 in the prior year comparable period.”
Prestige Consumer Healthcare Inc. reported the fiscal quarter and six months ended September 30, 2022 results: revenue $289.3 million, net income $51.0 million, EPS $1.02. Guidance reaffirmed.
“herein by reference. --- EX-99.1 (EX-99.1) --- Prestige Consumer Healthcare Inc. Reports Second Quarter Results and Reaffirms Outlook for Fiscal 2023 ◦ Record Revenue of $289.3 Million in Q2 fiscal 2023 increased 4.7% versus Prior Year and 5.5% excluding Currency ◦ Diluted EPS of $1.02 for Q2, ahead of expectations ◦ Reduced Debt by $35 million in Q2 and”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.